Cargando…
Characterization of SNF472 pharmacokinetics and efficacy in uremic and non-uremic rats models of cardiovascular calcification
End-stage renal disease is strongly associated with progressive cardiovascular calcification (CVC) and there is currently no therapy targeted to treat CVC. SNF472 is an experimental formulation under development for treatment of soft tissue calcification. We have investigated the pharmacokinetics of...
Autores principales: | Ferrer, Miguel D., Ketteler, Markus, Tur, Fernando, Tur, Eva, Isern, Bernat, Salcedo, Carolina, Joubert, Pieter H., Behets, Geert J., Neven, Ellen, D’Haese, Patrick C., Perelló, Joan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5942814/ https://www.ncbi.nlm.nih.gov/pubmed/29742152 http://dx.doi.org/10.1371/journal.pone.0197061 |
Ejemplares similares
-
SNF472, a novel inhibitor of vascular calcification, could be administered during hemodialysis to attain potentially therapeutic phytate levels
por: Perelló, Joan, et al.
Publicado: (2018) -
Trial design and baseline characteristics of CaLIPSO: a randomized, double-blind placebo-controlled trial of SNF472 in patients receiving haemodialysis with cardiovascular calcification
por: Bellasi, Antonio, et al.
Publicado: (2019) -
Calcific uremic arteriolopathy
por: Olaoye, Olanrewaju A, et al.
Publicado: (2017) -
Uremic Vascular Calcification: The Pathogenic Roles and Gastrointestinal Decontamination of Uremic Toxins
por: Chao, Chia-Ter, et al.
Publicado: (2020) -
Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis — Subgroup Analyses of the CALIPSO Trial
por: Raggi, Paolo, et al.
Publicado: (2020)